Fubotv earnings beat by $0.10, revenue topped estimates
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 186 shares of common stock on August 4, 2025, at a price of $28.364, for a total value of $5275. The transaction comes as TWST trades near its 52-week low of $27.12, with the stock experiencing significant volatility, having declined about 21% in the past week and 49% over six months.
Following the transaction, Werner directly owns 49,780 shares of Twist Bioscience. The company maintains strong liquidity with a current ratio of 3.9x and holds more cash than debt on its balance sheet.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by Twist Bioscience’s equity incentive plans. InvestingPro analysis reveals 12 additional key insights about TWST’s financial health and market position, available in the comprehensive Pro Research Report.
In other recent news, Twist Bioscience reported a notable 18% year-over-year increase in revenue for Q3 2025, reaching $96.1 million. Despite the revenue growth, the company faced an adjusted EBITDA loss of $8 million, although this was an improvement from the previous fiscal year. In addition to financial updates, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee.
On the analyst front, JPMorgan lowered its price target for Twist Bioscience to $25 from $33, maintaining an Underweight rating. TD Cowen also reduced its price target to $36 from $58, but kept a Buy rating, citing a change in the company’s fiscal year 2025 guidance due to a key customer’s transition phase. Meanwhile, Evercore ISI adjusted its price target to $46 from $50, maintaining an Outperform rating, following what it described as strong performance in the next-generation sequencing segment. These developments reflect a mix of strategic changes and financial performance adjustments for Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.